Skip to main content
Figure 3 | Journal of Experimental & Clinical Cancer Research

Figure 3

From: Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type

Figure 3

Overall survival of GBM patients in the mutant-type and wild-type IDH1 groups. A. Patients with mutant-type IDH1 had much better outcome than those with wild-type IDH1. B. Kaplan-Meier curves for the low-score and high-score groups. In the 140 IDH1 wild-type GBM patients, patients in the high-score group had much longer overall survival times than those in the low-score group.

Back to article page